title: Urinary endothelin-1-like immunoreactivity in young male patients with testicular cancer treated by cis-platinum: comparison with other urinary parameters.
abstract: 1. Urinary excretion of endothelin-1-like immunoreactivity and urinary excretion of other parameters (beta 2-microglobulin, N-acetyl-beta-D-glucosaminidase and microalbumin) were measured before, within 1 week after and 2 weeks after the administration of cis-platinum in five young male patients with testicular cancer (mean age 33.0 years) and were compared. 2. Urinary endothelin-1-like immunoreactivity/creatinine during, 1 week after, and 2 weeks after cis-platinum treatment was significantly higher than before cis-platinum. There was no difference in urinary endothelin-1-like immunoreactivity/creatinine during, 1 week after and 2 weeks after cis-platinum. 3. Among the four parameters, urinary endothelin-1-like immunoreactivity/creatinine showed the highest level after cis-platinum treatment. Urinary beta 2-microglobulin/creatinine most rapidly returned to normal levels after cis-platinum. 4. Although urinary endothelin-1-like immunoreactivity/creatinine did not show any significant correlations with urinary N-acetyl-beta-D-glucosaminidase (r = 0.291, not significant) or urinary microalbumin/creatinine (r = 0.076, not significant), it showed a significant correlation with urinary beta 2-microglobulin/creatinine (r = 0.475, P < 0.05). 5. These results suggest that endothelin-1 may be a sensitive urinary parameter in detecting cis-platinum-induced renal tubular injury.
authors.affiliation: Department of Urology, Niigata University School of Medicine, Japan.
authors.forename: M
authors.initials: M
authors.lastname: Takeda
authors.forename: T
authors.initials: T
authors.lastname: Komeyama
authors.forename: T
authors.initials: T
authors.lastname: Tsutsui
authors.forename: T
authors.initials: T
authors.lastname: Mizusawa
authors.forename: H
authors.initials: H
authors.lastname: Go
authors.forename: A
authors.initials: A
authors.lastname: Hatano
authors.forename: T
authors.initials: T
authors.lastname: Tanikawa
mesh_terms: D000118:Acetylglucosaminidase / Q000652:urine; D000328:Adult; D000971:Antineoplastic Combined Chemotherapy Protocols / Q000627:therapeutic use*; D014408:Biomarkers, Tumor / Q000652:urine*; D001761:Bleomycin / Q000008:administration & dosage; D002945:Cisplatin / Q000008:administration & dosage / Q000009:adverse effects*; D003404:Creatinine / Q000652:urine; D016232:Endothelins / Q000652:urine*; D005047:Etoposide / Q000008:administration & dosage; D006801:Humans; D007684:Kidney Tubules / Q000187:drug effects; D008297:Male; D013736:Testicular Neoplasms / Q000188:drug therapy / Q000652:urine*; D014747:Vinblastine / Q000008:administration & dosage; D001613:beta 2-Microglobulin / Q000652:urine
chemical_list: D014408:Biomarkers, Tumor; D016232:Endothelins; D001613:beta 2-Microglobulin; D001761:Bleomycin; D014747:Vinblastine; D005047:Etoposide; D003404:Creatinine; D000118:Acetylglucosaminidase; D002945:Cisplatin